Exogenous and endogenous hormones and breast cancer

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 22, Issue 4, 2008, Pages 573-585

  Chen, Wendy Y ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

breast cancer; estrogen; hormone replacement therapy; sex steroids

Indexed keywords

ANDROSTENEDIONE; AROMATASE; CATECHOL METHYLTRANSFERASE; CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; CYTOCHROME P450 17; CYTOCHROME P450 1B1; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; ETHINYLESTRADIOL; GESTAGEN; MEDROXYPROGESTERONE ACETATE; PLACEBO; PRASTERONE; PROGESTERONE; PROGESTERONE RECEPTOR; RALOXIFENE; SEROTONIN UPTAKE INHIBITOR; SEX HORMONE; TAMOXIFEN; TESTOSTERONE; TIBOLONE;

BODY MASS; BONE DENSITY; BREAST CANCER; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; DISEASE ASSOCIATION; ESTROGEN SYNTHESIS; FAMILY HISTORY; GENETIC POLYMORPHISM; HORMONE BLOOD LEVEL; HORMONE SUBSTITUTION; HUMAN; MEDICAL RESEARCH; MENOPAUSAL SYNDROME; OBESITY; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; RISK ASSESSMENT; TREATMENT DURATION; WEIGHT GAIN;

BREAST NEOPLASMS; ESTROGENS; FEMALE; GONADAL STEROID HORMONES; HORMONE REPLACEMENT THERAPY; HUMANS;

EID: 54849426520     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beem.2008.08.001     Document Type: Review

References (52)

1. Beatson G.T. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet 148 3802 (July 11, 1896) 104-107
2. Pike M.C., Karilo M., Henderson B.E., et al. 'Hormonal' risk factors, 'breast tissue age' and the age-incidence of breast cancer. Nature 303 (1983) 767-770
3. Ravdin P.M., Cronin K.A., Howlader N., et al. The decrease in breast-cancer incidence in 2003 in the United States. The New England Journal of Medicine 356 16 (Apr 19 2007) 1670-1674
4. Beral V. Breast cancer and hormone-replacement therapy in the million women study. Lancet 362 9382 (Aug 9 2003) 419-427
5. Hersh A.L., Stefanick M.L., and Stafford R.S. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. The Journal of the American Medical Association 291 1 (Jan 7 2004) 47-53
6. Watson J., Wise L., and Green J. Prescribing of hormone therapy for menopause, tibolone, and bisphosphonates in women in the UK between 1991 and 2005. European Journal of Clinical Pharmacology 63 9 (Sep 2007) 843-849
7. Faber A., Bouvy M.L., Loskamp L., et al. Dramatic change in prescribing of hormone replacement therapy in the Netherlands after publication of the Million Women Study: a follow-up study. British Journal of Clinical Pharmacology 60 6 (Dec 2005) 641-647
8. Rossouw J.E., Anderson G.L., Prentice R.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. The Journal of the American Medical Association 288 3 (2002) 321-333
9. Anderson G.L., Limacher M., Assaf A.R., et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. The Journal of the American Medical Association 291 14 (Apr 14 2004) 1701-1712
10. Chlebowski R.T., Hendrix S.L., Langer R.D., et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative randomized trial. The Journal of the American Medical Association 289 24 (Jun 25 2003) 3243-3253
11. McTiernan A., Martin C.F., Peck J.D., et al. Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial. Journal of the National Cancer Institute 97 18 (Sep 21 2005) 1366-1376
12. Stefanick M.L., Anderson G.L., Margolis K.L., et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. The Journal of the American Medical Association 295 14 (Apr 12 2006) 1647-1657
13. Collaborative group on hormonal factors in breast cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. [see comments] [published erratum appears in Lancet 1997 Nov 15;350(9089):1484]. Lancet 350 9084 (1997) 1047-1059
14. American College of Obstetricians and Gynecologists Women's Health Care Physicians. Executive summary. Hormone therapy. Obstetrics and Gynecology 104 4 Suppl (Oct 2004) 1S-4S
15. U.S. Preventive Services Task Force. Hormone therapy for the prevention of chronic conditions in postmenopausal women: recommendations from the U.S. preventive services task force. Annals of Internal Medicine 142 10 (May 17 2005) 855-860
16. Vassilopoulou-Sellin R., Cohen D.S., Hortobagyi G.N., et al. Estrogen replacement therapy for menopausal women with a history of breast carcinoma: results of a 5-year, prospective study. Cancer 95 9 (Nov 1 2002) 1817-1826
17. von Schoultz E., and Rutqvist L.E. Menopausal hormone therapy after breast cancer: the Stockholm randomized trial. Journal of the National Cancer Institute 97 7 (Apr 6 2005) 533-535
18. Holmberg L., Iversen O.E., Rudenstam C.M., et al. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. Journal of the National Cancer Institute 100 (2008) 475-482
19. Graham J.D., and Clarke C.L. Physiological action of progesterone in target tissues. Endocrine Reviews 18 4 (Aug 1997) 502-519
20. Chen W.Y., Manson J.E., Hankinson S.E., et al. Unopposed estrogen therapy and the risk of invasive breast cancer. Archives of Internal Medicine 166 9 (May 8 2006) 1027-1032
21. Chen W.Y., and Colditz G.A. Risk factors and hormone-receptor status: epidemiology, risk-prediction models and treatment implications for breast cancer. Nature Clinical Practice. Oncology 4 7 (Jul 2007) 415-423
22. Stahlberg C., Pedersen A.T., Lynge E., et al. Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in Europe. International Journal of Cancer 109 5 (May 1 2004) 721-727
23. Fournier A., Berrino F., and Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Research and Treatment 107 1 (Jan 2008) 103-111
24. Tamimi R.M., Hankinson S.E., Chen W.Y., et al. Combined estrogen and testosterone use and risk of breast cancer in postmenopausal women. Archives of Internal Medicine 166 14 (Jul 24 2006) 1483-1489
25. Ewertz M. Influence of non-contraceptive exogenous and endogenous sex hormones on breast cancer risk in Denmark. International Journal of Cancer 42 6 (Dec 15 1988) 832-838
26. van den Brandt P.A., Spiegelman D., Yaun S.S., et al. Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. American Journal of Epidemiology 152 6 (Sep 15 2000) 514-527
27. Lahmann P.H., Hoffmann K., Allen N., et al. Body size and breast cancer risk: findings from the European Prospective Investigation into Cancer And Nutrition (EPIC). International Journal of Cancer 111 5 (Sep 20 2004) 762-771
28. Eliassen A.H., Colditz G.A., Rosner B., et al. Adult weight change and risk of postmenopausal breast cancer. The Journal of the American Medical Association 296 2 (Jul 12 2006) 193-201
29. Key T.J., Appleby P.N., Reeves G.K., et al. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. Journal of the National Cancer Institute 95 16 (Aug 20 2003) 1218-1226
30. Lukanova A., Lundin E., Zeleniuch-Jacquotte A., et al. Body mass index, circulating levels of sex-steroid hormones, IGF-I and IGF-binding protein-3: a cross-sectional study in healthy women. European Journal of Endocrinology 150 2 (Feb 2004) 161-171
31. Cauley J.A., Lucas F.L., Kuller L.H., et al., Study of Osteoporotic Fractures Research Group. Bone mineral density and risk of breast cancer in older women: the study of osteoporotic fractures. [see comments]. The Journal of the American Medical Association 276 17 (1996) 1404-1408
32. Zhang Y., Kiel D.P., Kreger B.E., et al. Bone mass and the risk of breast cancer among postmenopausal women. The New England Journal of Medicine 336 9 (Feb 27 1997) 611-617
33. Kerlikowske K., Shepherd J., Creasman J., et al. Are breast density and bone mineral density independent risk factors for breast cancer?. Journal of the National Cancer Institute 97 5 (Mar 2 2005) 368-374
34. Wang S., Paris F., Sultan C.S., et al. Recombinant cell ultrasensitive bioassay for measurement of estrogens in postmenopausal women. The Journal of Clinical Endocrinology and Metabolism 90 3 (Mar 2005) 1407-1413
35. Lippman M.E., Krueger K.A., Eckert S., et al. Indicators of lifetime estrogen exposure: effect on breast cancer incidence and interaction with raloxifene therapy in the multiple outcomes of raloxifene evaluation study participants. Journal of Clinical Oncology 19 12 (Jun 15 2001) 3111-3116
36. Key T., Appleby P., Barnes I., et al. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. Journal of the National Cancer Institute 94 8 (Apr 17 2002) 606-616
37. Missmer S.A., Eliassen A.H., Barbieri R.L., et al. Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. Journal of the National Cancer Institute 96 24 (Dec 15 2004) 1856-1865
38. Kaaks R., Rinaldi S., Key T.J., et al. Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition. Endocrine-Related Cancer 12 4 (Dec 2005) 1071-1082
39. Hankinson S.E., Manson J.E., Spiegelman D., et al. Reproducibility of plasma hormone levels in postmenopausal women over a 2-3-year period. Cancer Epidemiology, Biomarkers & Prevention 4 6 (1995) 649-654
40. Kaaks R., Berrino F., Key T., et al. Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC). Journal of the National Cancer Institute 97 10 (May 18 2005) 755-765
41. Eliassen A.H., Missmer S.A., Tworoger S.S., et al. Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women. Journal of the National Cancer Institute 98 19 (Oct 4 2006) 1406-1415
42. Costantino J.P., Gail M.H., Pee D., et al. Validation studies for models projecting the risk of invasive and total breast cancer incidence. Journal of the National Cancer Institute 91 18 (1999) 1541-1548
43. Eliassen A.H., Missmer S.A., Tworoger S.S., et al. Endogenous steroid hormone concentrations and risk of breast cancer: does the association vary by a woman's predicted breast cancer risk?. Journal of Clinical Oncology 24 12 (Apr 20 2006) 1823-1830
44. Cuzick J., Powles T., Veronesi U., et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 361 9354 (2003) 296-300
45. Fisher B., Costantino J.P., Wickerham D.L., et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. Journal of the National Cancer Institute 97 22 (Nov 16 2005) 1652-1662
46. Vogel V.G., Costantino J.P., Wickerham D.L., et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP study of tamoxifen and raloxifene (STAR) P-2 trial. The Journal of the American Medical Association 295 23 (Jun 21 2006) 2727-2741
47. Cummings S.R., Duong T., Kenyon E., et al. Serum estradiol level and risk of breast cancer during treatment with raloxifene. The Journal of the American Medical Association 287 2 (Jan 9 2002) 216-220
48. Beattie M.S., Costantino J.P., Cummings S.R., et al. Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1). Journal of the National Cancer Institute 98 2 (Jan 18 2006) 110-115
49. Kuiper G.G., Carlsson B., Grandien K., et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 138 3 (Mar 1997) 863-870
50. Blankenstein M.A., van de Ven J., Maitimu-Smeele I., et al. Intratumoral levels of estrogens in breast cancer. The Journal of Steroid Biochemistry and Molecular Biology 69 1-6 (Apr-Jun 1999) 293-297
51. Geisler J. Breast cancer tissue estrogens and their manipulation with aromatase inhibitors and inactivators. The Journal of Steroid Biochemistry and Molecular Biology 86 3-5 (Sep 2003) 245-253
52. Kendall A., Folkerd E.J., and Dowsett M. Influences on circulating oestrogens in postmenopausal women: relationship with breast cancer. The Journal of Steroid Biochemistry and Molecular Biology 103 2 (Feb 2007) 99-109